Video
Author(s):
Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.
Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.
Editor’s note: Transcript lightly edited for clarity.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Companies announce presentations at upcoming 2025 ARVO Annual Meeting